1 min read
Add as a preferred source on Google

20/20 BioLabs' Q3 Loss Widens to $1.38 Million as Revenue Drops 9%

GAAP loss per share narrowed to $0.12. OneTest revenue rose 4.1% in the first nine months of 2026.

A diagnostic test cartridge rests on a stainless laboratory bench / TokenPost.ai
A diagnostic test cartridge rests on a stainless laboratory bench / TokenPost.ai

20/20 BioLabs, Inc. (Nasdaq: AIDX) recorded a 9% year-over-year revenue decline to $380,216 for the third quarter, while its net loss grew to $1.38 million.

The loss compared with $830,000 in the year-earlier quarter. The company’s GAAP loss per share narrowed to $0.12 from $0.17.

For the first nine months of 2026, OneTest revenue rose 4.1% to $1.36 million. The product’s gross margin increased to 32.8% from 29.5%.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…